CloudDX wins IRAP funding for monitoring device
August 26, 2020
KITCHENER, Ont – Cloud DX, a leading provider of telehealth and remote patient monitoring solutions, announced that it is receiving advisory services and phase 1 research and development funding of up to $300,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to prove the feasibility of a low-cost solution for continuous monitoring of patient vitals, including heart rate, temperature, oxygen concentration, blood pressure and respiration rate.
This funding comes as part of the “Low-cost sensor system for COVID-19 patient monitoring” challenge issued by NRC IRAP through the federal government’s Innovative Solutions Canada (ISC) program. If successful, phase 2 funding could be awarded to develop a working prototype.
Pending Health Canada approvals, the solution, an adaptation of the company’s award-winning VITALITI™ continuous vital signs monitor, would be used for at-home monitoring of Canadians who have been diagnosed with COVID-19, helping alleviate pressure on a potentially overburdened healthcare system.
“Sudden changes that signify a rapid deterioration in patient condition can make the difference between life and death in someone who has contracted COVID-19. Continuous monitoring of key vital signs allows home-bound COVID+ and high-risk patients and their caregivers to make better decisions as to whether care should be escalated, while offering reassurance to others whose condition is stable. It also helps public health officials best determine how to deploy scarce resources,” said Robert Kaul (pictured), CEO of Cloud DX.
“By reducing the hardware costs for the VITALITI™ continuous vital sign monitor (CVSM) we can eliminate one of the biggest barriers to remote patient monitoring (RPM) adoption – affordability – and help more healthcare providers across Canada provide high quality “hospital-level” care to patients recovering at home.”
Cloud DX’s existing VITALITI™ CVSM prototype already meets many of the expected outcomes set out in NRC IRAP’s ISC challenge. The new design will significantly reduce hardware and assembly costs while creating a more comfortable and durable system that can be cleaned and disinfected between users. The NRC IRAP funding – and the potential to access future Phase 2 funding of up to $2 million – stands to provide Cloud DX with the necessary resources to realize its vision for low-cost, high-quality product design, rapid Health Canada approval and a fully commercialized solution in record time.
The VITALITI™ continuous vital sign monitor (CVSM) is among the most advanced wearables ever designed, measuring ECG, heart rate, oxygen saturation, respiration, core body temperature, blood pressure, movement, steps & posture along with advanced power management enabling 72 hours of comfortable wear. VITALITI™ earned Cloud DX the Bold Epic Innovator Award as one of three winners of the Qualcomm Tricorder XPRIZE competition in 2017.
About Cloud DX
Cloud DX is a leader in digital healthcare with rapidly growing sales across North America. Our complete remote patient monitoring platform incorporates proprietary medical devices, mobile apps, clinical dashboards, artificial intelligence and EMR integration. In one recent third-party study, Cloud DX technology reduced hospital admissions due to COPD while achieving 100% patient satisfaction. The company is the co-winner of the Qualcomm Tricorder XPRIZE, a Fast Company “World Changing Idea” finalist and the recent winner of the Waterloo MedTech Startup to Scale Up Award of Excellence.